利用癌症药物查询数据库(CanMED)-国家药品代码(NDC):评估全身乳腺癌治疗模式。
Utilization of the Cancer Medications Enquiry Database (CanMED)-National Drug Codes (NDC): Assessment of Systemic Breast Cancer Treatment Patterns.
机构信息
Surveillance Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, Rockville, MD.
Information Management Services, Inc., Calverton, MD.
出版信息
J Natl Cancer Inst Monogr. 2020 May 1;2020(55):46-52. doi: 10.1093/jncimonographs/lgaa002.
Cancer Medications Enquiry Database (CanMED) is comprised of two interactive, nomenclature-specific databases within the Observational Research in Oncology Toolbox: CanMED-Healthcare Common Procedure Coding System (HCPCS) and CanMED-National Drug Code (NDC), described through this study. CanMED includes medications with a) a US Food and Drug Administration-approved cancer treatment or treatment-related symptom management indication, b) inclusion in treatment guidelines, or c) an orphan drug designation. To demonstrate the joint utility of CanMED, medication codes associated with female breast cancer treatment were identified and utilization patterns were assessed within Surveillance Epidemiology and End Results-Medicare (SEER) data. CanMED-NDC (11_2018 v.1.2.4) includes 6860 NDC codes: chemotherapy (1870), immunotherapy (164), hormone therapy (3074), and ancillary therapy (1752). Treatment patterns among stage I-IIIA (20 701) and stage IIIB-IV (2381) breast cancer patients were accordant with guideline-recommended treatment by stage and molecular subtype. CanMED facilitates identification of medications from observational data (eg, claims and electronic health records), promoting more standardized and efficient treatment-related cancer research.
癌症药物查询数据库 (CanMED) 由观察性肿瘤学工具包中的两个交互式、专门术语特定数据库组成:CanMED-医疗保健通用程序代码系统 (HCPCS) 和 CanMED-国家药物代码 (NDC),本研究对其进行了描述。CanMED 包括具有以下特征的药物:a) 美国食品和药物管理局批准的癌症治疗或与治疗相关的症状管理适应症,b) 纳入治疗指南,或 c) 孤儿药指定。为了展示 CanMED 的联合效用,确定了与女性乳腺癌治疗相关的药物代码,并在监测流行病学和最终结果-医疗保险 (SEER) 数据中评估了其使用模式。CanMED-NDC(11_2018 v.1.2.4)包含 6860 个 NDC 代码:化疗 (1870)、免疫疗法 (164)、激素疗法 (3074) 和辅助疗法 (1752)。I-IIIA 期 (20701) 和 IIIB-IV 期 (2381) 乳腺癌患者的治疗模式与基于阶段和分子亚型的指南推荐治疗一致。CanMED 有助于从观察性数据 (例如,索赔和电子健康记录) 中识别药物,从而促进更标准化和高效的与治疗相关的癌症研究。